Literature DB >> 3688024

Linear growth response to exogenous growth hormone in Prader-Willi syndrome.

P D Lee1, D M Wilson, L Rountree, R L Hintz, R G Rosenfeld.   

Abstract

Linear growth retardation and adult short stature are usual characteristics of Prader-Willi syndrome. Several lines of evidence suggest that a deficiency in growth hormone (GH) secretion may contribute to this abnormal growth pattern. We have recently reported observations in 4 children with Prader-Willi syndrome treated with GH. This report extends our observations in 2 of these cases. Both cases had abnormally low growth rate, normal stimulated GH levels, and low somatomedin-C levels prior to therapy. GH treatment led to significant increases in linear growth rate and somatomedin-C levels. An additive effect of oxandrolone therapy on linear growth rate was demonstrated in one case. Our results support the possibility of a neuro-secretory GH deficiency in Prader-Willi syndrome and suggest a need for further investigations.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3688024     DOI: 10.1002/ajmg.1320280411

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  10 in total

1.  Effect of growth hormone on height, weight, and body composition in Prader-Willi syndrome.

Authors:  P S Davies; S Evans; S Broomhead; H Clough; J M Day; A Laidlaw; N D Barnes
Journal:  Arch Dis Child       Date:  1998-05       Impact factor: 3.791

Review 2.  The Prader-Willi syndrome.

Authors:  M D Donaldson; C E Chu; A Cooke; A Wilson; S A Greene; J B Stephenson
Journal:  Arch Dis Child       Date:  1994-01       Impact factor: 3.791

3.  Impairment of growth hormone responsiveness to growth hormone releasing hormone and pyridostigmine in patients affected by Prader-Labhardt-Willi syndrome.

Authors:  L Beccaria; F Benzi; A Sanzari; L Bosio; P Brambilla; G Chiumello
Journal:  J Endocrinol Invest       Date:  1996-11       Impact factor: 4.256

4.  The growth hormone response to hexarelin in patients with Prader-Willi syndrome.

Authors:  M Cappa; G Raguso; T Palmiotto; A Faedda; F Gurreri; G Neri; R Deghenghi; S Loche
Journal:  J Endocrinol Invest       Date:  1998-09       Impact factor: 4.256

5.  Growth hormone secretion in Prader-Willi syndrome.

Authors:  S Grosso; M Cioni; S Buoni; L Peruzzi; L Pucci; R Berardi
Journal:  J Endocrinol Invest       Date:  1998 Jul-Aug       Impact factor: 4.256

6.  Prader-Willi syndrome: current understanding of cause and diagnosis.

Authors:  M G Butler
Journal:  Am J Med Genet       Date:  1990-03

Review 7.  GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome.

Authors:  Cheri L Deal; Michèle Tony; Charlotte Höybye; David B Allen; Maïthé Tauber; Jens Sandahl Christiansen
Journal:  J Clin Endocrinol Metab       Date:  2013-03-29       Impact factor: 5.958

8.  Changes in body composition, blood lipid profile, and growth factor hormone in a patient with Prader-willi syndrome during 24 weeks of complex exercise: a single case study.

Authors:  Hee Joung Joung; In Soo Lim
Journal:  J Exerc Nutrition Biochem       Date:  2018-03-30

Review 9.  Prader-Willi syndrome and growth hormone deficiency.

Authors:  Zehra Aycan; Veysel Nijat Baş
Journal:  J Clin Res Pediatr Endocrinol       Date:  2014

Review 10.  Human Growth and Growth Hormone: From Antiquity to the Recominant Age to the Future.

Authors:  Evan Graber; Edward O Reiter; Alan D Rogol
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-05       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.